JP2022521818A5 - - Google Patents
Info
- Publication number
- JP2022521818A5 JP2022521818A5 JP2021557342A JP2021557342A JP2022521818A5 JP 2022521818 A5 JP2022521818 A5 JP 2022521818A5 JP 2021557342 A JP2021557342 A JP 2021557342A JP 2021557342 A JP2021557342 A JP 2021557342A JP 2022521818 A5 JP2022521818 A5 JP 2022521818A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823374P | 2019-03-25 | 2019-03-25 | |
| US62/823,374 | 2019-03-25 | ||
| US201962874773P | 2019-07-16 | 2019-07-16 | |
| US62/874,773 | 2019-07-16 | ||
| PCT/US2020/024654 WO2020198323A1 (en) | 2019-03-25 | 2020-03-25 | Prmt5 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521818A JP2022521818A (ja) | 2022-04-12 |
| JP2022521818A5 true JP2022521818A5 (enExample) | 2023-04-03 |
| JP7609798B2 JP7609798B2 (ja) | 2025-01-07 |
Family
ID=72609147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557342A Active JP7609798B2 (ja) | 2019-03-25 | 2020-03-25 | Ｐｒｍｔ５インヒビター及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12583859B2 (enExample) |
| EP (1) | EP3947387B1 (enExample) |
| JP (1) | JP7609798B2 (enExample) |
| KR (1) | KR20220023330A (enExample) |
| CN (1) | CN114127072B (enExample) |
| AU (1) | AU2020245480A1 (enExample) |
| BR (1) | BR112021019125A2 (enExample) |
| CA (1) | CA3134779A1 (enExample) |
| IL (2) | IL318073A (enExample) |
| MX (1) | MX2021011524A (enExample) |
| SG (1) | SG11202110272SA (enExample) |
| WO (1) | WO2020198323A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| CN117157297A (zh) * | 2021-07-20 | 2023-12-01 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| EP4458836A4 (en) * | 2021-12-27 | 2025-05-21 | Riken Genesis Co., Ltd. | Novel artificial nucleic acid, method for producing same, and use of same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| KR102028793B1 (ko) | 2013-03-14 | 2019-10-07 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) * | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11059850B2 (en) * | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
-
2020
- 2020-03-25 IL IL318073A patent/IL318073A/en unknown
- 2020-03-25 MX MX2021011524A patent/MX2021011524A/es unknown
- 2020-03-25 KR KR1020217034437A patent/KR20220023330A/ko not_active Ceased
- 2020-03-25 SG SG11202110272SA patent/SG11202110272SA/en unknown
- 2020-03-25 EP EP20778402.6A patent/EP3947387B1/en active Active
- 2020-03-25 CA CA3134779A patent/CA3134779A1/en active Pending
- 2020-03-25 AU AU2020245480A patent/AU2020245480A1/en not_active Abandoned
- 2020-03-25 BR BR112021019125A patent/BR112021019125A2/pt not_active IP Right Cessation
- 2020-03-25 CN CN202080037608.5A patent/CN114127072B/zh active Active
- 2020-03-25 JP JP2021557342A patent/JP7609798B2/ja active Active
- 2020-03-25 WO PCT/US2020/024654 patent/WO2020198323A1/en not_active Ceased
- 2020-03-25 US US17/598,152 patent/US12583859B2/en active Active
-
2021
- 2021-09-23 IL IL286622A patent/IL286622A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022521818A5 (enExample) | ||
| JP2022507514A5 (enExample) | ||
| RU2441005C2 (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| JP2021512059A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| RU2475484C2 (ru) | Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака | |
| RU2003118446A (ru) | Пролекарства цианогуанидина | |
| JP2018138577A5 (enExample) | ||
| JP2021510376A5 (enExample) | ||
| JP2023509366A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2009543771A5 (enExample) | ||
| JP2013522292A5 (enExample) | ||
| JP2021516242A5 (enExample) | ||
| RU2008122046A (ru) | Аминопиримидины в качестве ингибиторов киназ | |
| JP2014527082A5 (enExample) | ||
| JP2010530885A5 (enExample) | ||
| RU2007130076A (ru) | Антагонисты cxcr4 для лечения внутренних болезней | |
| JP2023526283A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2004520282A5 (enExample) | ||
| JP2016534134A5 (enExample) | ||
| JP2022526220A5 (enExample) | ||
| JP2023508328A5 (enExample) | ||
| Jung et al. | Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene) thiazolidine-2, 4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling |